History of peripheral artery disease and cardiovascular risk of real-word patients with acute coronary syndrome: Role of inflammation and comorbidities

Autor: Denegri, Andrea, Magnani, Giulia, Kraler, Simon, Bruno, Francesco, Klingenberg, Roland, Mach, Francois, Gencer, Baris, Räber, Lorenz, Rodondi, Nicolas, Rossi, Valentina A, Matter, Christian M, Nanchen, David, Obeid, Slayman, Lüscher, Thomas F

Publikováno v: Denegri, Andrea; Magnani, Giulia; Kraler, Simon; Bruno, Francesco; Klingenberg, Roland; Mach, Francois; Gencer, Baris; Räber, Lorenz; Rodondi, Nicolas; Rossi, Valentina A; Matter, Christian M; Nanchen, David; Obeid, Slayman; Lüscher, Thomas F (2023). History of peripheral artery disease and cardiovascular risk of real-word patients with acute coronary syndrome: Role of inflammation and comorbidities. International journal of cardiology, 382, pp. 76-82. Elsevier 10.1016/j.ijcard.2023.03.043
International journal of cardiology, vol. 382, pp. 76-82

BACKGROUND Patients with acute coronary syndromes (ACS) remain at risk of cardiovascular disease (CVD) recurrences. Peripheral artery disease (PAD) may identify a very high risk (VHR) group who may derive greater benefit from intensified secondary pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49a15a9966eb26e2f992e7bff87a6bdc
https://boris.unibe.ch/180603/8/Denegri_IntJCardiol_2023.pdf

Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84):A Retrospective Cohort Study

Autor: Olulade Ayodele, Fan Mu, Richard Berman, Elyse Swallow, Lars Rejnmark, Elvira O. Gosmanova, Sanjiv Kaul

Publikováno v: Ayodele, O, Mu, F, Berman, R, Swallow, E, Rejnmark, L, Gosmanova, E O & Kaul, S 2022, ' Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84) : A Retrospective Cohort Study ', Advances in Therapy, vol. 39, no. 8, pp. 3845-3856 . https://doi.org/10.1007/s12325-022-02198-y

INTRODUCTION: Patients with chronic hypoparathyroidism are at increased risk of cardiovascular disease. This study evaluated the risk of developing cardiovascular conditions over a period of 5 years in adult patients with chronic hypoparathyroidism t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff5923b5cd658602d96a46616c7f82d
https://pure.au.dk/portal/da/publications/lower-risk-of-cardiovascular-events-in-adult-patients-with-chronic-hypoparathyroidism-treated-with-rhpth184(2bf6bf50-a466-43ef-bbcb-e8ef204c36a9).html

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Autor: Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, Matthew A Cavender, Anna Norhammar, Marit E Jørgensen, Kåre I Birkeland, Reinhard W Holl, Josep Franch-Nadal, Navdeep Tangri, Jonathan E Shaw, Jenni Ilomäki, Avraham Karasik, Su-Yen Goh, Chern-En Chiang, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, Mikhail Kosiborod, John P Wilding, Kamlesh Khunti, Kåre Birkeland, Marit Eika Jørgensen, Reinhard W. Holl, Carolyn SP Lam, Hanne Løvdal Gulseth, Bendix Carstensen, Esther Bollow, Luis Alberto García Rodríguez, Jonathan Shaw, Suzanne Arnold, Betina T. Blak, Eric T. Wittbrodt, Matthias Saathoff, Yusuke Noguchi, Donna Tan, Maro Williams, Hye Won Lee, Maya Greenbloom, Oksana Kaidanovich-Beilin, Khung Keong Yeo, Yong Mong Bee, Joan Khoo, Agnes Koong, Yee How Lau, Fei Gao, Wee Boon Tan, Hanis Abdul Kadir, Kyoung Hwa Ha, Jinhee Lee, Gabriel Chodick, Cheli Melzer-Cohen, Reid Whitlock, Lucia Cea-Soriano, Oscar Fernándex Cantero, Jordan A. Menzin, Matthew Guthrie, Jennie Ilomaki, Dianna Magliano

Publikováno v: Kohsaka, S, Lam, C S P, Kim, D J, Cavender, M A, Norhammar, A, Jørgensen, M E, Birkeland, K, Holl, R W, Franch-Nadal, J, Tangri, N, Shaw, J, Ilomäki, J, Karasik, A, Goh, S Y, Chiang, C E, Thuresson, M, Chen, H, Wittbrodt, E, Bodegård, J, Surmont, F, Fenici, P & Kosiborod, M 2020, ' Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors : an analysis from the CVD-REAL 2 multinational cohort study ', The Lancet Diabetes and Endocrinology, vol. 8, no. 7, pp. 606-615 . https://doi.org/10.1016/S2213-8587(20)30130-3
Lancet Diabetes & Endocrinology, 8(7), 606-615. ELSEVIER SCIENCE INC

Background: Cardiovascular outcome trials have shown cardiovascular benefit with sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors have not shown an effect. We aimed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68860c6556bbf38e0e25d66268d78e6f
https://doi.org/10.1016/s2213-8587(20)30130-3

Considérations pratiques pour l’utilisation des inhibiteurs du SGLT2 dans les maladies cardiovasculaires [Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases]

Autor: Lu, H., Hullin, R., Yerly, P., Meyer, P., Kosinski, C., Daux, A.

Publikováno v: Revue medicale suisse, vol. 17, no. 740, pp. 1034-1038

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs which offer cardiovascular (CV) and renal benefits. They are currently indicated as first-line treatments of type 2 diabetes mellitus (T2DM) in patients with CV disease, high CV r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::68472c38c8f1eb8f3f7a8a91d41b1767
https://serval.unil.ch/resource/serval:BIB_7FA860CBBECC.P001/REF.pdf

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Autor: David C. Wheeler, Tom Greene, John J.V. McMurray, Hiddo J.L. Heerspink, Robert D. Toto, Anna Maria Langkilde, Glenn M. Chertow, Bergur V. Stefánsson, Fan Fan Hou, Ricardo Correa-Rotter, Dapa-Ckd Trial Committees, Investigators, Peter Rossing, C. David Sjöström, Niels Jongs

Publikováno v: Lancet Diabetes & Endocrinology, 9(1), 22-31. ELSEVIER SCIENCE INC
DAPA-CKD Trial Committees and Investigators 2021, ' Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial ', The Lancet Diabetes and Endocrinology, vol. 9, no. 1, pp. 22-31 . https://doi.org/10.1016/S2213-8587(20)30369-7

Background: Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, cardiovascular, and mortality outcomes according to presence or ab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3a1159f26d848e4b231091b2729525
https://research.rug.nl/en/publications/92ee2074-5922-4044-aceb-cfcbddfff59c